Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns “Buy” Rating from Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. Chardan Capital’s price target would suggest a potential upside of 129.45% from the stock’s previous close.

Several other brokerages have also recently issued reports on ARWR. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. B. Riley restated a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Piper Sandler restated an “overweight” rating and set a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $42.56.

Arrowhead Pharmaceuticals Trading Up 24.2 %

NASDAQ:ARWR opened at $26.15 on Wednesday. The business’s 50-day moving average is $19.95 and its 200 day moving average is $23.18. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $39.83. The company has a market capitalization of $3.25 billion, a P/E ratio of -5.60 and a beta of 0.93.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ARWR. Fifth Third Bancorp grew its stake in shares of Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares during the last quarter. Values First Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Meeder Asset Management Inc. grew its position in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the last quarter. nVerses Capital LLC bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at $96,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.